Linear accelerators (linacs) are used to deliver radiation therapy to destroy cancer cells, and online adaptive radiotherapy (OART) enables clinicians to tailor each treatment session daily to the patient’s anatomy. The radiotherapy plans are reoptimized based on daily imaging of the patients. This allows for highly precise, targeted treatments which can help to minimize damage to surrounding healthy tissue and therefore reduce patient side effects. Until now, the vast majority of OART treatments have been delivered on purpose-built, specialized machines, which most hospitals do not have access to.

The Royal Marsden’s achievement demonstrates that OART can be performed on more widely available linacs, which are already being used for radiotherapy delivery, bringing this highly precise treatment to even more patients. For The Royal Marsden, it represents an important step toward being able to provide online adaptive treatments whenever clinically appropriate, using any suitable machine within their radiotherapy departments.

Online adaptive radiotherapy was first demonstrated at The Royal Marsden in March 2025 on an Accuray Radixact® system using RayStation®, and the team has been delivering routine online adaptive treatments on Radixact ever since. The Accuray Radixact® system and RayStation® at The Royal Marsden were funded by The Royal Marsden Cancer Charity.

The successful treatment on an Elekta linac, using the same principles as for Radixact, confirms a quick transition of the workflows to another delivery system and proves the clinical readiness, speed, and robustness of the RayStation module for adaptive replanning. It also highlights the potential for broad adoption of online adaptive radiotherapy in routine care. RaySearch and The Royal Marsden will continue to collaborate closely to further streamline workflows, enhance system interoperability, and extend usage to additional machine types.

Johan Löf, founder and CEO, RaySearch:
“Online adaptive radiotherapy on widely used C-arm linacs is a game changer, made possible entirely by software, and we are impressed by The Royal Marsden’s achievement in bringing this into clinical practice across their network of radiotherapy departments. This milestone lays the foundation for making online adaptive radiotherapy accessible to more patients and centers worldwide.

For more information, please contact:
Johan Löf, founder and CEO, RaySearch Laboratories AB
Telephone: +46 (0) 8 510 530 00

Carolina Strömlid, Head of Investor Relations, RaySearch Laboratories AB
Telephone: +46 (0) 708 807 173 
ir@raysearchlabs.com

About The Royal Marsden NHS Foundation Trust  

• The Royal Marsden opened in 1851 as the world’s first hospital dedicated to cancer diagnosis, treatment, research and education. Today it operates as a specialist cancer centre and is ranked in the top 10 specialised hospitals in the world.
• The Trust was delighted to welcome Her Royal Highness The Princess of Wales as Joint Patron with His Royal Highness The Prince of Wales, in January 2025.
• Together with its principal academic partner, The Institute of Cancer Research, London, The Royal Marsden is designated as the UK’s only National Institute for Health and Care Research (NIHR) Biomedical Research Centre (BRC) dedicated solely to cancer.
• The Royal Marsden and the Institute of Cancer Research (ICR) are recognised as one of the top four comprehensive cancer centres in the world for the impact of their research, influencing cancer treatment and care for cancer patients globally.
• As a centre of excellence, The Royal Marsden pioneers the very latest in cancer treatments and technologies, as well as leading the way in innovative cancer diagnosis and education.

About RaySearch
RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation®* treatment planning system (TPS) and the oncology information system (OIS) RayCare®*. The most recent additions to the RaySearch product line are RayIntelligence® and RayCommand®*. RayIntelligence is an oncology analytics system (OAS) which enables cancer clinics to collect, structure and analyze data. RayCommand, a treatment control system (TCS), is designed to link the treatment machine and the treatment planning and oncology information systems. RaySearch’s software has been sold to nearly 1,200 clinics in 51 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003 (STO: RAY B). More information is available at raysearchlabs.com.

* Subject to regulatory clearance in some markets.

Learn more about us on:
LinkedIn
YouTube